Sun Pharmaceutical Industries has received approval for a weight loss injection similar to Novo Nordisk’s Wegovy. The new treatment, called “SUN-144”, is a once-weekly injection that helps with weight management in adults with obesity or overweight with at least one weight-related condition. This approval marks a significant milestone for Sun Pharma, as it enters the growing market for anti-obesity treatments.<\/p>\n
Wegovy, a glucagon-like peptide-1 (GLP-1) receptor agonist, has been highly successful in treating obesity, with sales exceeding $1 billion in 2022. SUN-144 is also a GLP-1 receptor agonist, which works by mimicking a natural hormone that helps regulate appetite and food intake. Clinical trials have shown that SUN-144 is effective in reducing body weight and improving glycemic control in patients with type 2 diabetes.<\/p>\n
The approval of SUN-144 is expected to increase competition in the anti-obesity market, which is currently dominated by Novo Nordisk’s Wegovy and Saxenda. However, Sun Pharma’s entry into the market may also lead to increased accessibility and affordability of these treatments, which could benefit patients who struggle with obesity and related health conditions.<\/p>\n
Sun Pharma’s SUN-144 has shown promising results in clinical trials, with significant weight loss and improvements in cardiovascular risk factors. The treatment has also been well-tolerated, with common side effects including nausea, vomiting, and diarrhea. As the global prevalence of obesity continues to rise, the demand for effective and safe treatments is increasing. Sun Pharma’s entry into the market is expected to help meet this demand and provide patients with more options for managing their weight and related health conditions.<\/p>\n
The approval of SUN-144 is a significant achievement for Sun Pharma, which has been expanding its portfolio of specialty and generic products. The company has a strong presence in the pharmaceutical industry, with a global footprint and a wide range of products. With the launch of SUN-144, Sun Pharma is poised to become a major player in the anti-obesity market, which is expected to continue growing in the coming years. As the company prepares to launch SUN-144, it is likely to focus on educating healthcare professionals and patients about the benefits and risks of the treatment, as well as its potential to improve health outcomes for individuals with obesity and related conditions.<\/p>\n","protected":false},"excerpt":{"rendered":"
Sun Pharmaceutical Industries has received approval for a weight loss injection similar to Novo Nordisk’s Wegovy. The new treatment, called “SUN-144”, is a once-weekly injection that helps with weight management in adults with obesity or overweight with at least one weight-related condition. This approval marks a significant milestone for Sun Pharma, as it enters the […]<\/p>\n","protected":false},"author":1,"featured_media":88143,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","fifu_image_url":"","fifu_image_alt":"","_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[2,16],"tags":[],"class_list":["post-89871","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pharma","category-sun-pharma"],"jetpack_featured_media_url":"https:\/\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png","jetpack_sharing_enabled":true,"jetpack-related-posts":[{"id":89842,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/23\/sun-pharma-receives-dcgi-approval-for-generic-version-of-wegovy-plans-march-release-ahead-of-semaglutide-patent-expiration\/","url_meta":{"origin":89871,"position":0},"title":"Sun Pharma receives DCGI approval for generic version of Wegovy, plans March release ahead of Semaglutide patent expiration.","author":"Team Small News","date":"January 23, 2026","format":false,"excerpt":"Sun Pharmaceutical Industries has received approval from the Drugs Controller General of India (DCGI) to launch a generic version of Novo Nordisk's Wegovy, a medication used to treat obesity. The approval comes as the patent for the active ingredient, semaglutide, is set to expire in March 2023. Wegovy, which contains\u2026","rel":"","context":"In "Pharma"","block_context":{"text":"Pharma","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/pharma\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":89790,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/12\/lupin-partners-with-gan-lee-to-bring-fortnightly-glp-1-treatment-to-india-through-exclusive-licensing-deal\/","url_meta":{"origin":89871,"position":1},"title":"Lupin partners with Gan & Lee to bring fortnightly GLP-1 treatment to India through exclusive licensing deal.","author":"Team Small News","date":"January 12, 2026","format":false,"excerpt":"Lupin Limited, a global pharmaceutical company, has entered into an exclusive agreement with Gan&Lee Pharmaceuticals of China to commercialize Bofanglutide, a novel GLP-1 receptor agonist, in India. Bofanglutide is a fortnightly treatment for type 2 diabetes and weight management in overweight and obese adults, offering a reduced injection frequency compared\u2026","rel":"","context":"In "Lupin"","block_context":{"text":"Lupin","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/lupin\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":89762,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/07\/the-high-court-has-asked-novo-nordisk-to-respond-to-natcos-request-to-cancel-its-patent\/","url_meta":{"origin":89871,"position":2},"title":"The High Court has asked Novo Nordisk to respond to Natco’s request to cancel its patent.","author":"Team Small News","date":"January 7, 2026","format":false,"excerpt":"The Delhi High Court has ordered Novo Nordisk, a Danish pharmaceutical company, to respond to a petition filed by Natco Pharma, a Hyderabad-based company, seeking to revoke the patent on the diabetes and anti-obesity drug semaglutide. The patent, which is set to expire in March, has been a subject of\u2026","rel":"","context":"In "Natco"","block_context":{"text":"Natco","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/natco\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":89862,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/26\/several-major-indian-pharmaceutical-companies-including-sun-pharma-cipla-zydus-and-graviti-have-issued-recalls-for-certain-medications-in-the-united-states-market\/","url_meta":{"origin":89871,"position":3},"title":"Several major Indian pharmaceutical companies, including Sun Pharma, Cipla, Zydus, and Graviti, have issued recalls for certain medications in the United States market.","author":"Team Small News","date":"January 26, 2026","format":false,"excerpt":"Several major pharmaceutical companies, including Sun Pharma, Cipla, Zydus, and Graviti Pharmaceuticals, are recalling various products in the US due to manufacturing issues, according to recent US FDA enforcement reports. The recalls are primarily related to problems with impurities, quality control, and production processes. Sun Pharma is recalling over 24,000\u2026","rel":"","context":"In "Cipla"","block_context":{"text":"Cipla","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/cipla\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":89739,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/02\/sun-pharma-wins-reprieve-as-cestat-sends-back-rs-3-90-crore-excise-demand-for-re-assessment-over-eou-dta-sales-and-deemed-exports-juris-hour\/","url_meta":{"origin":89871,"position":4},"title":"Sun Pharma Wins Reprieve as CESTAT Sends Back Rs. 3.90 Crore Excise Demand for Re-Assessment Over EOU DTA Sales and Deemed Exports – Juris Hour","author":"Team Small News","date":"January 2, 2026","format":false,"excerpt":"The Customs, Excise, and Service Tax Appellate Tribunal (CESTAT) has remanded a Rs. 3.90 crore excise demand against Sun Pharmaceutical Industries Ltd. regarding sales from an Export Oriented Unit (EOU) to a Domestic Tariff Area (DTA). The tribunal has directed the authorities to recalculate the deemed exports and the corresponding\u2026","rel":"","context":"In "Pharma"","block_context":{"text":"Pharma","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/pharma\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":89821,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/19\/sun-pharma-sets-sights-on-10-billion-organon-takeover-to-bolster-us-presence\/","url_meta":{"origin":89871,"position":5},"title":"Sun Pharma Sets Sights on $10 Billion Organon Takeover to Bolster US Presence","author":"Team Small News","date":"January 19, 2026","format":false,"excerpt":"Sun Pharmaceutical Industries Ltd., India's largest drug manufacturer, is considering a monumental acquisition of Organon, a US-based company specializing in women's health and biosimilars. The potential deal, valued at $10 billion, is being led by the company's founder, Dilip Shanghvi. If successful, this acquisition would be a significant milestone for\u2026","rel":"","context":"In "Pharma"","block_context":{"text":"Pharma","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/pharma\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"_links":{"self":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/posts\/89871","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/comments?post=89871"}],"version-history":[{"count":0,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/posts\/89871\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/media\/88143"}],"wp:attachment":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/media?parent=89871"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/categories?post=89871"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/tags?post=89871"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}